CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
B 细胞恶性肿瘤 CAR-T 细胞治疗后的继发性恶性肿瘤：一项回顾性分析
英文原题：Secondary Malignancies Following CAR T-Cell Therapy for B-Cell Malignancies: A Retrospective Analysis.
查看英文原题
Secondary Malignancies Following CAR T-Cell Therapy for B-Cell Malignancies: A Retrospective Analysis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
继发恶性肿瘤的发生是 CAR-T 治疗后的潜在并发症。
中文摘要
方法
研究者对前瞻性收集的单中心队列开展回顾性分析，共纳入2020年1月至2023年8月接受CAR-T 治疗复发/难治性B细胞恶性肿瘤的87例患者。
结果
7例患者（8.0%）发生继发性恶性肿瘤，年龄中位数为57岁（40–77岁），从CAR-T 治疗到发病的平均时间为16.9个月（3–34.5个月）。其中2例确诊骨髓增生异常综合征（MDS），5例确诊急性髓系白血病（AML）。6例患者确诊MDS/AML时存在细胞遗传学异常。5例接受去甲基化药物治疗，2例接受异基因造血干细胞移植治疗髓系恶性肿瘤。诊断髓系恶性肿瘤后12个月，2例患者仍存活。12个月累积发生率（CIF）为2.3%（95%置信区间0.4%–7.3%），24个月CIF为6.9%（95%置信区间2.4%–14.4%）。
结论
继发性恶性肿瘤是CAR-T 治疗后可能发生的并发症。本单中心研究结果需由更大规模多中心研究加以验证。试验注册：作者确认本投稿无需临床试验注册。
展开英文摘要原文
METHODS
We performed a single-center retrospective analysis of a prospectively collected cohort of 87 patients who received CART therapy for relapsed/refractory B-cell malignancies between January 2020 and August 2023.
RESULTS
Seven patients (8.0%) developed a secondary malignancy, with a median age of 57 years (40-77) and mean time to onset of 16.9 months (3-34.5 months). Two patients were diagnosed with MDS and five with AML. Six patients had cytogenetic abnormalities at diagnosis of MDS/AML. Five patients received hypomethylating agents and two received an allogeneic stem cell transplant as treatment for their myeloid malignancy. Two patients were alive at 12 months after diagnosis of their myeloid malignancy. The 12-month cumulative incidence function (CIF) was 2.3% (95% CI, 0.4%-7.3%) and the 24-month CIF was 6.9% (95% CI, 2.4%-14.4%).
CONCLUSION
Development of a secondary malignancy is a potential complication following CART therapy. Results of this single-center study should be confirmed with larger multicenter studies. Trial Registration : The authors have confirmed clinical trial registration is not needed for this submission.
论文信息
- 作者
- Britto J、Dong AYH、Pond G、Berg T、Lepic K、Kouroukis T、Davies GA、Fraser G
- 第一作者单位
- Faculty of Health Sciences McMaster University Hamilton Ontario Canada.Canada
- 通讯作者单位
- Department of Oncology McMaster University Hamilton Ontario Canada.Canada
- 期刊
- EJHaem2025 Dec
- 原文标识
- PubMed 41163847 · DOI 10.1002/jha2.70164
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →